Visible science

Nicox develops innovative therapeutics to help maintain vision and improve ocular health

October 2025

Learn more about the mechanism of action of NCX 470, our lead product candidate in glaucoma

Nicox Provides First Half 2025 Financial Results
October 23, 2025 Read more
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
October 2, 2025 Read more
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
September 4, 2025 Read more